# Syros Pharmaceuticals, Inc. (SYRS)

> Source: Nexqual · https://nexqual.com/SYRS · data as of 2026-10-21 20:00 UTC · cite as "Nexqual, Syros Pharmaceuticals, Inc. (SYRS), nexqual.com/SYRS" · informational, not investment advice.

**Price:** USD 0 (+0.00% on the day) · last close of Oct 21, 2026; US market pre market, not a live price. Prev close 0 · day 0–0 · 52w 0–0.02 · market cap $11K · PNK

## Key facts
- Analysts: None (4 analysts), mean target USD 8.75 (range 4–20).
- Total return with dividends: 1Y -33.3% vs S&P 500 +14.9%; 5Y -100.0% vs S&P 500 +80.3%.

## Analysts
Consensus None, 4 analysts; mean target USD 8.75 (low 4, high 20).

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-23) | 5Y (from 2021-10-18) |
|---|---|---|
| Total return | -33.3% | -100.0% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | -33.4% | -90.1% |
| Volatility (annualized) | 1032.0% | 388.5% |
| Max drawdown | -96.7% (Sep 2026→Sep 2026) | -100.0% (Nov 2021→Sep 2025) |

## Peers (Biotechnology)
RYTM (Rhythm Pharmaceuticals, Inc.) USD 90.9 +2.57% · LGND (Ligand Pharmaceuticals Incorpor) USD 307.82 -2.21% · IOVA (Iovance Biotherapeutics, Inc.) USD 14.14 -3.28% · PRAX (Praxis Precision Medicines, Inc) USD 258.92 +0.96% · IONS (Ionis Pharmaceuticals, Inc.) USD 43.91 -0.81% · ABVX (Abivax SA) USD 90.23 -3.49%

## More
Full page: https://nexqual.com/SYRS · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2024-12-31) | — | — | — | $0 | — |
| Next quarter (ends 2025-03-31) | $-0.71 | $-0.75 | -5.8% | $0 | 3 |
| Current fiscal year (ends 2024-12-31) | — | — | — | $0 | — |
| Next fiscal year (ends 2025-12-31) | $-2.61 | $-2.26 | +15.2% | $0 | 4 |